Analyst Ratings For G1 Therapeutics
In the last three months, 8 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX), offering a diverse range…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) fell sharply during Tuesday’s session after the company announced the pricing…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Sharps Technology (NASDAQ:STSS) stock rose 140.0% to $0.51 during Tuesday’s regular session. The company’s market cap stands…
What’s Going On With G1 Therapeutics Stock?
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday’s regular session. The company’s market cap stands…
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on G1 Therapeutics…
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
In the preceding three months, 5 analysts have released ratings for G1 Therapeutics (NASDAQ:GTHX), presenting a wide array…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday’s pre-market session. The market value of…
Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Updates on trial progress, interim analysis, and potential FDA filing in 2024.